NURS 6630 Week 8 assignment Case Study Week 8 Comorbid Addictions NURS 6630 Week 8 assignment Case Study Week 8 Comorbid Addictions   NURS 6630 Week 8 assignment Case Study Week 8 Comorbid Addiction

********** ***** ***************************** Approaches ** ********* ** PsychopathologyWalden ***************** MarkhamJune ** 2019            AbstractThe purpose ** **** ***** is to examine *** **** ****** ** ******* Hispanic Man with Major ********** ******** It **** cover *** ***** ******** ****** ****** ********* **** ******* *** medications ********** ********* *** pharmacokinetic *** pharmacodynamic ********* **** ******** ** the **** *** *********** will ***** *** each decision *** ****** *** *** ********* behind ***** ********************************* ** a Hispanic *********** **** **** *** ** **** ** ******* **** *** ****** ** * ***** age ***** *** ****** *** died ************* ******* **** ** always **** **** ** ******** ** ** was ************ * lot *** being ‘black’ ** high school He states **** ** *** few ******* *** **** ** ******* He **** ******* * ********** ********** ******** in ******** in ***** activities states **** ** *** ****** 15 ****** in *** **** *** monthsHe is **** ******** **** insomnia ***** ***** about *** ****** ago but *** **** ************* ******* ***** ** does ****** **** ************* ***** ** ******* is ******* in ************* ** **************** ********* 2016g) *** *********** Asberg ********** Rating ***** ******* is 51 *********** ************* Point ***** ******** ***** *** ***** *** ***** choices ** *********** Zoloft 25 ** ***** ******* ** *** ***** *** phenelzine ** mg TID * chose Effexor XR 375mg ***** The *** ****** ******** *** have ****** ** ********* ********** of ************** * ******* that ******* Zoloft *** Effexor I **** ** get *** **** **** for my **** ****** ** ** SSRI ***** ******* ** a **** serotonin *** ************** ******** **************** ***** * ****** I should ** *** *** gusto *** treat *** neurotransmitters ****** **** *************** medications *** have ********* ********** *** ******************* ************ ****** ethnic *** ****** ******** *** study ******* **** ***** ** **** **** side ******* **** ***** ****** Interethnic *********** in **** ********** by *** ********** enzyme ****** may *********** ******* **** ********** ** ********* ********* ******* *** ***** environmental factors *** ****** ************** metabolism ** **** *** ******** ** **** ****** *** ***** *************** *********** ** efficacy *** ******************* of **************** *************** **** *** ***** ********* *********************** Das ******** ******** ***** Olfson ************ ** ** ******* ***** ********* *** ************** reuptake *********** ***** ********** ** ** ************** *** ** is not **** ** antidepressant” **** medication **** ****** social ******* *** ******* ************* ***** This patient ******* social settings and **** ** himself **** a **** ***** *** ******* of ******** *** ********** from other ******** ** ****** *** harassment ***** ***** ****** ** *** **** ********* **** ****** ******* * also like ** because it ***** **** **** ********* and ***************** **** ****** * was given *** perfect ******* ********* ********** guide ********** *** mg for *** ******** dose which ** * *** **** ** Effexor As *** ******* *** **** ****** ** ****** side ******* * ******* ***** a *** **** *** minimize those effects ***** four weeks of ******* *** ******* ******* to *** clinic with ** ****** ** his **************** **** ****** ** give the ******* **** **** ** the **** **** because *** “onset ** therapeutic ******* ** *** usually ********* *** ***** delayed ***** ************** ***** That ** 2-4 weeks ****** *** ***** not **** **** ****** He ***** have **** ***** *** onset of action"If ** ** not ******* within ***** weeks *** ********** ** may ******* a ****** ******** ** it *** *** work ** ************ ***** *** ***** 2008 *********** ***** ******** that *********** is *** best *********** with *********** **** option *** *** a ****** ******* * ** *********** ********* **** obvious I know that ******** ************** ******* work well **** *************** but * learned **** **** studying ******* disorders *********** *********** ********* * want ** stick **** *** ********** **** ***** 2008 ************** ******** **** only * partial ******** ***** some ******** are improved *** ****** persist (especially ******** ******* *** ******** *********************** ***** *** *********** ***** **** ****** **** * *** **** to considerincreasing *** **** switching to ******* ***** ** adding ** *********** ********** ******** ****** ***** Well that **** led ** back ** *** ******************** ************* ************ *** demonstrated ** be efficacious ** ******************* ********** (TRD) ** ******** **************** ***** Woo *** *** ** & **** 2015) * ****** ******* **** patient ** treatment-resistant without a longer trial at *** ******* **** or ** ********* dose **** is * ***** ******** I ***** * **** increase *** dose ** that doesn’t work * **** try ** atypical ************** now doubt ** ******** ********* **** ********* ****** **** side effects *** **** ***** ****** ** lower ******* ** **** help **** is * ***** ***** ****** range **** * ** ******* that I should **** ***** *** ******** ************* *** *** **** of ********** ********** *** be affected ** *** **** ******* experienced **** non-Hispanics *** **** ****** to ** ********* when *** ****** of treatment ** *********** such ** *** *********** ******* ** *** * ** hopeful I ********* ****** ** patientand he ******* * *** ******** ** symptoms ** ***** he hasimprovement Although * am wondering ** he ********** **** **** ****** ** * *** ****** *** additional ********** *************** ThreeAt **** ***** * ** *** **** to increase *** dosage *** **** side effects **** **** result ** *** ******* ********** ********* of *** **** * ** ******** **** ****** Zoloft ******* ***** to **** *** ****** ********* this *** **** ****************** is a *********** reuptake ********* and ******** ************** ***** ***** ** is ***** ** **** with *** more ***************** *** * **** to ********** *** ******* ******* *** ******** ******* * ** ****** **** *** **** effect ******* be ******** *** this ******* ******* ** *** ********* *** ******* ************** I ** ***** **** *** ********* ** ** ****** ** **** **** **** **** too * **** ******** **** * have *** choice ** ******** with *** **** dosage ** *** ******* medicationConsidering **** *** ******* *** **** treated **** **** one ********** for eight weeks * ** ********* ** ****** *** ****** ** ******* *** ****** because **** improvement *** ***** ***** At **** ***** * just **** *** ******* to ******* ******* ****** ****** ******** *** this ******** I ** ******** *** ************** the ****** ** **** decision ***** **** been * conversation * ***** **** *** ****** ******** ***** * think ****** the *********** **** may **** *********** ** on what path ** choose * ***** ** ******* **** *** recommended ****** adding Wellbutrin Explain *** **** effects ** ********** *** ****** *** ******* to ****** **** ** ****** ********* and *** ********** ** ****** *** ********** **** **** ****** ***** **** ***** ** an **** ** whether ** *** *** possibility of **** ******* or the ********** **** ***** **** been **** detrimental to **** patient ************ ************************** of ********* in *** ********* of the ***** ********** ******** ***** continues to be a ***** ****** ****** ******* ********* **** out **** treatment *** ** three ***** **** ********** **** ************ ****** ******* *** ******** ** treatment ************ *** ********* and their *** rates of ******** into *** ****** ****** care ********* **** **** ***** *********** Institute; ******** ********* ** Mental ****** ******* *** **** ***** Psychiatric ********* ************** also ****** from side effects ** lower ***** *** more ******** **** ***** ********* ********* ** is vitally important for the ********** ********* ** major ********** ******** ** *** ******** **** ** avoid ******** that *** lead ** non-compliance or **** *** ** treatment *** goal **** be *** ***** The goal ** ******* improvement reduction ** **** effects **** * ****** treatment regime ** prevent **** *** *** ***** maximize effects * don’t **** ****** **** *** decisions * made **** the **** *** * ** *** ********* with ******** *** **** * **** *** ******* **** scenario *** ***** **** I **** *** ***** ******* over *** over until * achieve *** maximum *********** with the least **** effect * ** grateful *** this learning experience         ReferencesLaureate ********* ******* **** ****** An elderly Hispanic *** ********* ********** ******** *********** ***** **** ********* MD ******************* * Das * K ******** * ******** * M ***** ****** * ****** Depression in ** Hispanics: ********** *** ********** Considerations ** Family ******** ******* ** *** ******** Board ** Family ******** ***************** S * ****** * *** ********** ***** ******** to ** sensitive ** ****** ******* ******* of Psychiatry *** ********** York ***** *********** ********** ******** ********* of Mental ****** (NIMH); New York ***** Psychiatric ********* (2017 June *** ************* ******* ********* ****** ** ******* ********* Retention ** ********* ********* (National ******* of ********* Retrieved **** ******** ****** **** *************************************************** * * ****** Essential ****************** ******* ************ ***** **** *** ********* **** *************************************************************************************************************************************************************** H *** Y *** * *** ** * * ***** **** W-M (2015) **** ** Woo YS ***** ******** ************* ************ Reduce Subsequent Treatment ******* **** *********** Among ********* ******** **** * ****** Degree ** ********* *********** ************* Journal of *********************** ***** Retrieved **** ***********************************************************************************************

Click here to download attached files: docx-(5) (1).docx